<VariationArchive RecordType="classified" VariationID="2637704" VariationName="NM_024306.5(FA2H):c.911dup (p.Leu305fs)" VariationType="Duplication" Accession="VCV002637704" Version="1" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2023-11-25" DateCreated="2023-11-20" MostRecentSubmission="2023-11-20">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="2805181" VariationID="2637704">
      <GeneList>
        <Gene Symbol="FA2H" FullName="fatty acid 2-hydroxylase" GeneID="79152" HGNC_ID="HGNC:21197" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>16q23.1</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="16" Accession="NC_000016.10" start="74712969" stop="74774820" display_start="74712969" display_stop="74774820" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="16" Accession="NC_000016.9" start="74746852" stop="74808728" display_start="74746852" display_stop="74808728" Strand="-" />
          </Location>
          <OMIM>611026</OMIM>
        </Gene>
      </GeneList>
      <Name>NM_024306.5(FA2H):c.911dup (p.Leu305fs)</Name>
      <CanonicalSPDI>NC_000016.10:74716474:CCCCCC:CCCCCCC</CanonicalSPDI>
      <VariantType>Duplication</VariantType>
      <Location>
        <CytogeneticLocation>16q23.1</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="16" Accession="NC_000016.10" start="74716474" stop="74716475" display_start="74716474" display_stop="74716475" variantLength="1" positionVCF="74716474" referenceAlleleVCF="G" alternateAlleleVCF="GC" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="16" Accession="NC_000016.9" start="74750372" stop="74750373" display_start="74750372" display_stop="74750373" variantLength="1" positionVCF="74750372" referenceAlleleVCF="G" alternateAlleleVCF="GC" />
      </Location>
      <ProteinChange>L305fs</ProteinChange>
      <HGVSlist>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000016.10" sequenceAccession="NC_000016" sequenceVersion="10" change="g.74716480dup" Assembly="GRCh38">
            <Expression>NC_000016.10:g.74716480dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000016.9" sequenceAccession="NC_000016" sequenceVersion="9" change="g.74750378dup" Assembly="GRCh37">
            <Expression>NC_000016.9:g.74750378dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_017070.1" sequenceAccession="NG_017070" sequenceVersion="1" change="g.63357dup">
            <Expression>NG_017070.1:g.63357dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_024306.5" sequenceAccession="NM_024306" sequenceVersion="5" change="c.911dup" MANESelect="true">
            <Expression>NM_024306.5:c.911dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_077282.3" sequenceAccession="NP_077282" sequenceVersion="3" change="p.Leu305fs">
            <Expression>NP_077282.3:p.Leu305fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_024306.5" sequenceAccession="NM_024306" sequenceVersion="5" change="c.911dupG" MANESelect="true">
            <Expression>NM_024306.5:c.911dupG</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
      </HGVSlist>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_024306.5(FA2H):c.911dup (p.Leu305fs) AND Hereditary spastic paraplegia 35" Accession="RCV003405002" Version="1">
        <ClassifiedConditionList TraitSetID="6693">
          <ClassifiedCondition DB="MedGen" ID="C3496228">Hereditary spastic paraplegia 35</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2023-10-12" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2023-10-12" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2023-11-20" MostRecentSubmission="2023-11-20">
        <ReviewStatus>criteria provided, single submitter</ReviewStatus>
        <Description>Pathogenic</Description>
        <ConditionList>
          <TraitSet ID="6693" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="4413" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Leukodystrophy, dysmyelinating, and spastic paraparesis with or without dystonia</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Spastic paraplegia 35</ElementValue>
                <XRef ID="Leukodystrophy%2C+dysmyelinating%2C+and+spastic+paraparesis+with+or+without+dystonia/4201" DB="Genetic Alliance" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Spastic paraplegia 35, autosomal recessive</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Hereditary spastic paraplegia 35</ElementValue>
                <XRef ID="MONDO:0012866" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">SPASTIC PARAPLEGIA 35, AUTOSOMAL RECESSIVE, WITH OR WITHOUT NEURODEGENERATION</ElementValue>
                <XRef Type="MIM" ID="612319" DB="OMIM" />
                <XRef Type="Allelic variant" ID="611026.0006" DB="OMIM" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">SPG35</ElementValue>
                <XRef Type="MIM" ID="612319" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Fatty acid hydroxylase-associated neurodegeneration (FAHN) is characterized early in the disease course by central nervous system involvement including corticospinal tract involvement (spasticity), mixed movement disorder (ataxia/dystonia), and eye findings (optic atrophy, oculomotor abnormalities), and later in the disease course by progressive intellectual impairment and seizures. With disease progression, dystonia and spasticity compromise the ability to ambulate, leading to wheelchair dependence. Life expectancy is variable. FAHN is considered to be a subtype of neurodegeneration with brain iron accumulation (NBIA).</Attribute>
                <XRef ID="NBK56080" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="10538" />
                <XRef ID="10538" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">21735565</ID>
                <ID Source="BookShelf">NBK56080</ID>
              </Citation>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">23447832</ID>
                <ID Source="BookShelf">NBK121988</ID>
              </Citation>
              <XRef ID="171629" DB="Orphanet" />
              <XRef ID="C3496228" DB="MedGen" />
              <XRef ID="MONDO:0012866" DB="MONDO" />
              <XRef Type="MIM" ID="612319" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="7702508" SubmissionDate="2023-11-14" DateLastUpdated="2023-11-20" DateCreated="2023-11-20">
        <ClinVarSubmissionID localKey="NM_024306.5:c.911dupG|MedGen:C3496228" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV004122831" DateUpdated="2023-11-20" DateCreated="2023-11-20" Type="SCV" Version="1" SubmitterName="Women's Health and Genetics/Laboratory Corporation of America, LabCorp" OrgID="500026" OrganizationCategory="laboratory" OrgAbbreviation="WHG-LC" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-10-12">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>Variant summary: FA2H c.911dupG (p.Leu305ProfsX8) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. The variant was absent in 250904 control chromosomes (gnomAD). To our knowledge, no occurrence of c.911dupG in individuals affected with Hereditary Spastic Paraplegia 35 and no experimental evidence demonstrating its impact on protein function have been reported. No submitters have cited clinical-significance assessments for this variant to ClinVar after 2014. Based on the evidence outlined above, the variant was classified as pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">LabCorp Variant Classification Summary - May 2015</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/api/2.0/files/rtxspsnt/labcorp_variant_classification_method_-_may_2015.pdf/?format=attachment</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="FA2H" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_024306.5:c.911dupG</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C3496228" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB13972740</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="7702508" TraitType="Disease" MappingType="XRef" MappingValue="C3496228" MappingRef="MedGen">
        <MedGen CUI="C3496228" Name="Hereditary spastic paraplegia 35" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

